ReLink is an advanced breakaway connector for IV lines, designed to reduce complications and costs associated with accidental disconnection events in healthcare settings, a leading challenge today for patients receiving hospital and home infusions.

Our first product ReLink Care is CE approved and available for sale.


The patented ReLink platform technology ensures delivery of critical fluids safely and efficiently.

ReLink® by Tada Group AB

Our focus is to develop and commercialise intuitive products designed for unmet clinical needs that add superior value to the healthcare system.

ReLink®- a breakaway connector for IV lines

The problem with Intravenous (IV) therapy

Intravenous (IV) therapy is the most common invasive procedure in modern healthcare, with fluids delivered directly into the vein through tubing connected to a catheter device. 

Research shows that around 16.6 billion tubes(1) are being used across the world today and ~10% of tubes are forcefully ripped from the vein during infusions(2). However, the problem is more serious than that. The PIVC failure rates and complication incidences are so high that approximately 1 out of every 2 catheters fail to make it to 5 days or to the end of treatment(3).

IV catheters are prone to mechanical complications such as phlebitis, infiltration and dislodgement resulting in catheter failure that happens at an alarming rate of 46%(4).

This IV catheter failure can result in injury to patients, loss of fluid resources, exposure of hazardous drugs and increased risk of infection. It also creates additional work for clinicians, with up to 18-44 mins of additional time required to clean and reinstate the infusion(5).

Infusion stability with ReLink

ReLink is a breakaway connector, designed and engineered to increase safety, accuracy, and efficiency of IV therapy in  healthcare settings.  

Its unique design features double-sided, self-sealable valves, with weak link activation to protect the catheter placement site and prevent loss of fluid resources. The pull force required to separate the tube from the catheter has been optimised through rigorous testing to ensure the catheter dwelling site remains protected.

After separation, both ReLink connector parts can be simply disinfected and reconnected for rapid reinstatement of therapy, providing unrivalled efficiency for nursing staff in every environment.

ReLink is specially engineered to enhance infusion stability by keeping connections of IV catheters to the patients with a controlled break away and predictable results. 

Hover over ReLink

ReLink®  product family

ReLink is a platform technology which is adaptable across a broad range of sectors...


ReLink Care

First generation single use breakaway connector for increased safety for patient and healthcare professionals. CE approved for gravitational IV. 

Hover over the image


ReLink Veterinary

Annual market value of €35 billion in Europe and USA. Low regulatory barrier for market entry. No product modifications required for treatment of small animals.

Hover over the image


ReLink Advanced

Next generation connector for pump driven infusions. Designed to meet the needs of all patient groups and be compatible with all IV fluids including blood and blood products.

Hover over the image


ReLink Digital

Moving IV therapy from the hospital to the home could save up to 90% of treatment costs. Continuity of care is enabled by including electronics for monitoring and communication.

Hover over the image

ReLink Logos_chemo-13-01.png

Closed System

A closed system connector device that eliminates leakage of toxic liquids and vapours to safekeep healthcare professionals working with hazardous drugs such as chemotherapy.

Hover over the image

ReLink Logos_antimicrobial-15.png


Breakaway connector with a functionalised surface for antimicrobial protection. Especially beneficial for immunocompromised patients and central line usage.

Hover over the image


Meet the team

 Katarina Hedbeck, CEO & Co-founder of Tada Medical AB

Katarina Hedbeck

Chief Executive Officer 

& Co-founder

Rebecca Bejhed, COO & Co-founder of Tada Medical AB

Dr. Rebecca Bejhed

Chief Operating Officer

& Co-founder


Christopher Blacker, MD

Medical Lead

& Co-founder

Chief Technical Officer


Pallavi Saksena

Maria Asif, CFO at Tada Medical AB

Maria Asif

Chief Financial Officer

Puneet Gaharana Chief Strategy Officer at Tada Medical AB

Puneet Gaharana

Chief Strategy Officer

Ujala-Bhardwaj Chief Regulatory Officer at Tada Medical AB

Dr. Ujala Bhardwaj

Chief Quality Officer

Design Manager

Tada Medical AB Team Sike Wan.jpg

Sike Wan, MD

HEOR & RWE Manager

Tada Medical AB Team Aneek Lal.jpg

Finance Controller

Tada-Medical-AB-Team-Elena Davydova.jpg

Elena Davydova

HR Manager



A snapshot of what's keeping us inspired, excited and busy! 

Follow us on:

social media icons_fb_grey.png
social media icons_fb_c.png
social media icons_li_grey.png
social media icons_li_c.png
social media icons_tw_grey.png
social media icons_tw_c.png
social media icons_ig_grey.png
social media icons_ig_c.png
social media icons_yt_grey.png
social media icons_yt_c.png
tada medical ab European Union

The project has received funding from the European Union's Horizon 2020 research and innovation programme under EIC Accelerator grant agreement No 961967, Fast Track to Innovation grant No 971225 and from the Eurostars-2 Joint Programme with co-funding from the European Union's Horizon 2020 research and innovation programme.


  1. Literature study data

  2. Chopra, V. et al. Peripherally inserted central catheter use in skilled nursing facilities: a pilot study. J. Am. Geriatr. Soc. 63, 1894–1899 (2015).

  3. Steere, L., Ficara, C., Davis, M., & Moureau, N. (2019). Reaching one peripheral intravenous catheter (PIVC) per patient visit with lean multimodal strategy: the PIV5Rights™ bundle. Journal of the Association for Vascular Access, 24(3), 31-43.

  4. Treffalls, J. A., Portillo, D. J., Friesenhahn, S., Copeland, G. B., & Hood, R. L. (2021). The Occurrence of Peripheral Intravenous Catheter Complications and an Evaluation of the Methods Utilized to Mitigate Them. J Nurs Patient Health Care, 3(1), 102.

  5. Literature study data

tada medical ab news 8.jpg

The project has received funding from EIT Health.